LeMaitre Vascular (LMAT) Upgraded by BidaskClub to Sell

BidaskClub upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong sell rating to a sell rating in a research report sent to investors on Tuesday.

Several other research analysts have also recently commented on the company. Benchmark cut LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, October 27th. Stifel Nicolaus reaffirmed a buy rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Zacks Investment Research cut LeMaitre Vascular from a buy rating to a hold rating in a research report on Wednesday, November 1st. Canaccord Genuity reduced their target price on LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a research report on Friday, October 27th. Finally, First Analysis cut LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 target price for the company. in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $32.20.

Shares of LeMaitre Vascular (NASDAQ:LMAT) traded up $0.10 during mid-day trading on Tuesday, reaching $32.84. The company had a trading volume of 70,911 shares, compared to its average volume of 124,600. The company has a market capitalization of $628.81, a PE ratio of 42.65, a P/E/G ratio of 2.51 and a beta of 0.54. LeMaitre Vascular has a 52-week low of $19.82 and a 52-week high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.20 by $0.05. The firm had revenue of $24.80 million during the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. LeMaitre Vascular’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the business earned $0.17 earnings per share. analysts predict that LeMaitre Vascular will post 0.84 EPS for the current fiscal year.

In other LeMaitre Vascular news, insider David B. Roberts sold 4,123 shares of LeMaitre Vascular stock in a transaction on Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the completion of the transaction, the insider now directly owns 24,482 shares of the company’s stock, valued at $786,851.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 23.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of LMAT. BNP Paribas Arbitrage SA lifted its holdings in shares of LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 3,716 shares during the period. Teachers Retirement System of The State of Kentucky bought a new position in shares of LeMaitre Vascular during the second quarter valued at $137,000. Victory Capital Management Inc. lifted its holdings in shares of LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock valued at $155,000 after acquiring an additional 2,667 shares during the period. Royce & Associates LP bought a new position in shares of LeMaitre Vascular during the second quarter valued at $156,000. Finally, Royal Bank of Canada lifted its holdings in shares of LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 4,505 shares during the period. 69.24% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://weekherald.com/2018/01/17/lemaitre-vascular-lmat-upgraded-by-bidaskclub-to-sell.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply